Payment overview · 2025
General Payments
$261.80
6 reported records · 3 companies
Healthcare provider profile · identity verified
Tony Nahhas, MD
Allopathic & Osteopathic Physicians|Internal Medicine · CHICAGO, IL · NPI 1285619056
Verified facts
What the public records show
CMS Open Payments records show Tony Nahhas, MD received $261.80 in general payments during 2025 across 6 reported records.
Novo Nordisk Inc accounted for 83.7% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 4 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Ozempic.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 65 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 39 claims for Rybelsus by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $219.04 | 83.7% | 4 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $22.56 | 8.6% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $20.20 | 7.7% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $164.99 | 3 |
| Education | $96.81 | 3 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $186.77 | 3 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $32.27 | 1 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $22.56 | 1 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $20.20 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Ozempic ozempic |
2025 | Ozempic | 2024 | 65 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
65 | 16 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
39 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 482 | 119 |
| Metformin Hcl | Metformin Hcl | 407 | 89 |
| Losartan Potassium | Losartan Potassium | 391 | 104 |
| Levothyroxine Sodium | Levothyroxine Sodium | 390 | 71 |
| Farxiga | Dapagliflozin Propanediol | 370 | 76 |
| Metoprolol Succinate | Metoprolol Succinate | 365 | 82 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 337 | 91 |
| Amlodipine Besylate | Amlodipine Besylate | 284 | 75 |
| Omeprazole | Omeprazole | 274 | 64 |
| Meloxicam | Meloxicam | 271 | 82 |
| Jardiance | Empagliflozin | 254 | 44 |
| Pantoprazole Sodium | Pantoprazole Sodium | 238 | 61 |
| Tamsulosin Hcl | Tamsulosin Hcl | 214 | 57 |
| Furosemide | Furosemide | 208 | 46 |
| Gabapentin | Gabapentin | 202 | 40 |
| Lisinopril | Lisinopril | 202 | 47 |
| Simvastatin | Simvastatin | 195 | 39 |
| Eliquis | Apixaban | 189 | 25 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 169 | 38 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 165 | 34 |
| Clopidogrel | Clopidogrel Bisulfate | 158 | 34 |
| Tradjenta | Linagliptin | 152 | 25 |
| Alprazolam | Alprazolam | 137 | 24 |
| Carvedilol | Carvedilol | 131 | 30 |
| Tramadol Hcl | Tramadol Hcl | 131 | 39 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 130 | 43 |
| Diclofenac Sodium | Diclofenac Sodium | 129 | 26 |
| Metoprolol Tartrate | Metoprolol Tartrate | 126 | 26 |
| Allopurinol | Allopurinol | 107 | 21 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 104 | 32 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 101 | 24 |
| Alendronate Sodium | Alendronate Sodium | 100 | 24 |
| Januvia | Sitagliptin Phosphate | 94 | 21 |
| Fluticasone Propionate | Fluticasone Propionate | 86 | 30 |
| Pravastatin Sodium | Pravastatin Sodium | 86 | 18 |
| Metformin Hcl Er | Metformin Hcl | 84 | 24 |
| Famotidine | Famotidine | 80 | 28 |
| Finasteride | Finasteride | 80 | 21 |
| Sertraline Hcl | Sertraline Hcl | 78 | 19 |
| Hydrochlorothiazide | Hydrochlorothiazide | 76 | 22 |
| Meclizine Hcl | Meclizine Hcl | 76 | 26 |
| Azithromycin | Azithromycin | 75 | 62 |
| Pregabalin | Pregabalin | 73 | 16 |
| Memantine Hcl | Memantine Hcl | 72 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 70 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 67 | 23 |
| Donepezil Hcl | Donepezil Hcl | 66 | suppressed |
| Ozempic | Semaglutide | 65 | 16 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 64 | 13 |
| Pioglitazone Hcl | Pioglitazone Hcl | 62 | 11 |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 59 | 13 |
| Duloxetine Hcl | Duloxetine Hcl | 56 | 12 |
| Pro Comfort Alcohol Pads | Alcohol Antiseptic Pads | 55 | 11 |
| Ezetimibe | Ezetimibe | 52 | 14 |
| Lorazepam | Lorazepam | 49 | suppressed |
| Linzess | Linaclotide | 48 | 11 |
| Celecoxib | Celecoxib | 47 | 18 |
| Glimepiride | Glimepiride | 47 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 47 | 11 |
| Zolpidem Tartrate | Zolpidem Tartrate | 47 | suppressed |
| Gemtesa | Vibegron | 46 | 12 |
| Escitalopram Oxalate | Escitalopram Oxalate | 43 | 13 |
| Montelukast Sodium | Montelukast Sodium | 42 | 13 |
| Enalapril Maleate | Enalapril Maleate | 41 | suppressed |
| Mirtazapine | Mirtazapine | 41 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 40 | suppressed |
| Ketoconazole | Ketoconazole | 39 | suppressed |
| Rybelsus | Semaglutide | 39 | suppressed |
| Entresto | Sacubitril/Valsartan | 38 | suppressed |
| Valsartan | Valsartan | 38 | suppressed |
| Clotrimazole | Clotrimazole | 37 | 17 |
| Hydralazine Hcl | Hydralazine Hcl | 37 | suppressed |
| Potassium Chloride | Potassium Chloride | 36 | suppressed |
| Hydrocortisone | Hydrocortisone | 35 | 11 |
| Quetiapine Fumarate | Quetiapine Fumarate | 34 | suppressed |
| Diazepam | Diazepam | 33 | suppressed |
| Ibuprofen | Ibuprofen | 33 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 32 | 14 |
| Dapagliflozin | Dapagliflozin Propanediol | 32 | 21 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 32 | 11 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 31 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 31 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 30 | suppressed |
| Baclofen | Baclofen | 29 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 29 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 29 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 28 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 28 | 25 |
| Doxycycline Hyclate | Doxycycline Hyclate | 28 | 20 |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 28 | suppressed |
| Spironolactone | Spironolactone | 28 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 27 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 26 | suppressed |
| Naproxen | Naproxen | 26 | suppressed |
| Nitroglycerin | Nitroglycerin | 26 | suppressed |
| Novolog Flexpen | Insulin Aspart | 26 | suppressed |
| Procto-Med Hc | Hydrocortisone | 26 | suppressed |
| Aripiprazole | Aripiprazole | 25 | suppressed |
| Lidocaine | Lidocaine | 25 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 23 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 23 | suppressed |
| Prednisone | Prednisone | 23 | 19 |
| Donepezil Hcl Odt | Donepezil Hcl | 22 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 22 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 21 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 21 | suppressed |
| Lovastatin | Lovastatin | 21 | suppressed |
| Nifedipine Er | Nifedipine | 21 | suppressed |
| Levetiracetam | Levetiracetam | 20 | suppressed |
| Metronidazole | Metronidazole | 20 | suppressed |
| Ssd | Silver Sulfadiazine | 20 | suppressed |
| Synthroid | Levothyroxine Sodium | 20 | suppressed |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 20 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 19 | 12 |
| Doxazosin Mesylate | Doxazosin Mesylate | 19 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 19 | 17 |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 19 | suppressed |
| Glipizide | Glipizide | 18 | suppressed |
| Alcohol Pads | Alcohol Antiseptic Pads | 17 | suppressed |
| Ammonium Lactate | Ammonium Lactate | 17 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 17 | suppressed |
| Atenolol | Atenolol | 16 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 16 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 15 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 14 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 14 | suppressed |
| Heparin Sodium | Heparin Sodium,porcine | 14 | suppressed |
| Levofloxacin | Levofloxacin | 14 | 12 |
| Paroxetine Hcl | Paroxetine Hcl | 14 | suppressed |
| Scopolamine | Scopolamine | 14 | suppressed |
| Silver Sulfadiazine | Silver Sulfadiazine | 14 | suppressed |
| Xarelto | Rivaroxaban | 14 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 13 | suppressed |
| Cilostazol | Cilostazol | 13 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 13 | 11 |
| Clonidine | Clonidine | 13 | suppressed |
| Digoxin | Digoxin | 13 | suppressed |
| Dropsafe Prep Pads | Alcohol Antiseptic Pads | 13 | suppressed |
| Namzaric | Memantine Hcl/Donepezil Hcl | 13 | suppressed |
| Neomycin-Polymyxin-Dexameth | Neomycin/Polymyxin B/Dexametha | 13 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 13 | suppressed |
| Telmisartan-Hydrochlorothiazid | Telmisartan/Hydrochlorothiazid | 13 | suppressed |
| Tetrabenazine | Tetrabenazine | 13 | suppressed |
| Torsemide | Torsemide | 13 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 12 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 12 | suppressed |
| Clonazepam | Clonazepam | 12 | suppressed |
| Fluticasone Propionate Hfa | Fluticasone Propionate | 12 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 12 | 12 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 12 | suppressed |
| Trulicity | Dulaglutide | 12 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 12 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 11 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 11 | suppressed |
| Halobetasol Propionate | Halobetasol Propionate | 11 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $261.80 · 6 records | Novo Nordisk Inc | EVENITY, FREESTYLE LIBRE 3, Ozempic, Wegovy | 2 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Ozempic play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Novo Nordisk Inc?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error